Q2
CTMX — Q2 2026 Financial Report Analysis
CytomX's Q2 2026 revenue fell 92% to $1.4M as legacy partner deals ended and the net loss widened to $20.7M on rising Varseta-M spend, but a $234M share sale and $37M Regeneron payment fund operations into at least 2H 2028.